Main navigation

Randomized Phase II Trial of single agent chemotherapy plus Nivolumab or single Agent Chemotherapy Alone in Patients with Advanced Squamous or Non-squamous NSCLC with Primary Resistance to Prior PD-1 or PD-L1 Inhibitor (LUN 15-233)